Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Arena Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsArena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc.

ACTIVE

10646 Science Center Dr, San Diego, California, United Stateswww.arenapharm.comPublic448 employeesEstablished: 1977-01-01

Also known as:

Arena Pharmaceuticals

Part of PFIZER INC.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

169

124 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1977

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

127

75.2%

Phase 2

18

10.7%

Phase 3

18

10.7%

Phase 2/3

1

0.6%

Trial Status Distribution

Active, not recruiting

123

72.8%

Completed

25

14.8%

Not yet recruiting

1

0.6%

Recruiting

13

7.7%

Terminated

5

3.0%

Unknown

2

1.2%

Clinical Trials

Trials sponsored by this organization (169)

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Mar 202416 participants

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Mar 202416 participants

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Aug 202242 participants

A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease

Active, not recruiting

Apr 20221,265 participants

A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn's Disease

Apr 20224 participants

A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitis

Active, not recruiting

Mar 2022372 participants

A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease

Active, not recruiting

Jan 20221,265 participants

A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease - CULTIVATE

Active, not recruiting

Dec 20211,265 participants

Page 1 of 22

Approvals

No approval data available

News

Advancements in Crohn's Disease Treatment: Emerging Therapies and Market Trends

• The Crohn's disease market is experiencing growth, driven by increasing prevalence and advances in treatment options, with the market size expected to increase from USD ~9,000 million in 2023. • Emerging therapies like mirikizumab, guselkumab and biosimilars of ustekinumab are showing promise in clinical trials, offering improved efficacy and targeted mechanisms of action for Crohn's disease management. • Pharmaceutical companies such as Eli Lilly, Janssen, Takeda, and Dong-A-ST are actively involved in developing and launching novel treatments, including biologics and biosimilars, to address unmet needs in Crohn's disease. • Clinical trials are focusing on histologic outcomes and endoscopic remission, indicating a shift towards more comprehensive assessments of treatment efficacy in Crohn's disease patients.

On this page

Overview
Clinical Trials169
Approvals
News1

Back to Organizations